远大医药：全球创新温度敏感性栓塞剂产品在中国开展的注册性临床研究完成全部患者入组

Core Viewpoint - The company, Far East Pharmaceutical, has completed patient enrollment for its innovative temperature-sensitive embolic agent GPN00289 in a clinical study for primary liver cancer in China, aiming to assess its safety and efficacy [1] Group 1 - The clinical study is a registration trial for GPN00289, specifically targeting transarterial chemoembolization for primary liver cancer [1] - The completion of patient enrollment marks a significant milestone in the development of GPN00289 [1]